WebDynaMed Plus® from EBSCO Health is an evidence-based tool that health professionals can use to inform clinical care. DynaMed Plus content undergoes a review process, and the evidence is synthesized in detailed topic overviews. A unique three-level rating scale is used to assess the qualit … WebMy Health Decisions content covers a variety of specialties and is designed to be easily digestible for patients. Developed by a team of clinical experts, using the most current evidence, the Option Grid patient decision aids found in My Health Decisions are focused on the questions patients most frequently ask when they need to make preference …
Congenital and Perinatal Cytomegalovirus Infection (CMV)
Webimmunoglobulin M (IgM) antibody to hepatitis A virus (anti-HAV) nucleic acid amplification test such as polymerase chain reaction (PCR) or genotyping; confirmed case of acute … About - Hepatitis A Virus (HAV) Infection - DynaMed WebCOVID-19 Presenting as Acute Hepatitis. COVID-19 Presenting as Acute Hepatitis Am J Gastroenterol. 2024 Jun;115(6):941-942. doi: 10.14309/ajg.0000000000000660. Authors Praneet Wander 1 , Marcia Epstein 2 , David Bernstein 1 Affiliations 1 Division of ... in east meadow
DynaMed Point of Care Clinical Decision Support Evidence …
WebEBV is a ubiquitous herpes virus with oncogenic potential (worldwide seroprevalence > 90%) 1,2,3 primary infection is often asymptomatic, but may present as infectious mononucleosis, especially in adolescents and adults 1,3; EBV establishes lifelong infection in B cells 1,2,3. long-term infection is benign in most hosts Webacute liver failure (ALF) is a rare, life-threatening condition of rapidly deteriorating liver function characterized by coagulation abnormality (usually INR ≥ 1.5) and any degree of mental alteration (encephalopathy) in patient without preexisting liver disease and with illness < 26 weeks duration 1,4,6. in the presence of associated abnormalities in liver … WebRecurrent hepatitis C virus infection is a challenging complication post-liver transplant. Current guidelines recommend the combination of ribavirin and ledipasvir/sofosbuvir for 12 weeks for the treatment of recurrent HCV genotype 1 post-liver in eastern usa the palmetto state